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SUMMARY
Cancers are believed to arise from cancer stem cells (CSCs), but it is not known if these cells remain
dependent upon the niche microenvironments that regulate normal stem cells. We show that endo-
thelial cells interact closely with self-renewing brain tumor cells and secrete factors that maintain
these cells in a stem cell-like state. Increasing the number of endothelial cells or blood vessels in
orthotopic brain tumor xenografts expanded the fraction of self-renewing cells and accelerated
the initiation and growth of tumors. Conversely, depletion of blood vessels from xenografts ablated
self-renewing cells from tumors and arrested tumor growth. We propose that brain CSCs are main-
tained within vascular niches that are important targets for therapeutic approaches.INTRODUCTION
There is now compelling evidence that the bulk of the
malignant cells in cancers are generated by rare fractions
of self-renewing, multipotent, and tumor-initiating cells,
termed cancer stem cells (CSCs) (Al-Hajj et al., 2003; Lap-
idot et al., 1994; Singh et al., 2004). Whether CSCs arise
from normal stem cells or more differentiated cells is not
known. Nevertheless, CSCs resemble the normal stem
or progenitor cells of the corresponding tissue of origin.
For example, brain CSCs express CD133 and Nestin
that mark neural stem and progenitor cells (Galli et al.,
2004; Singh et al., 2004; Taylor et al., 2005), and we
recently reported that CSCs isolated from ependymomas
are remarkably similar to radial glia that are neural precur-
sor cells (Taylor et al., 2005).
If tumors are derived entirely from CSCs, then drugs that
kill these cells could prove highly effective treatments of
cancer. On the other hand, the similarities between normal
and malignant stem cells predict that such treatments
may also possess significant toxicities. Recent encourag-ing data have provided proof of principle that selective
targeting of CSCs is possible (Yilmaz et al., 2006). How-
ever, the development of anti-CSC therapies for each
type of cancer is likely to require the identification of
factors that maintain CSCs, but not normal stem cells, in
each tissue.
One important difference between normal stem cells
and CSCs might be the degree to which these cells are
regulated by the immediate microenvironment. Stem cells
of various tissues exist within protective niches that are
composed of a number of differentiated cell types (Fuchs
et al., 2004; Moore and Lemischka, 2006). These mature
cells provide direct cell contacts and secreted factors
that maintain stem cells primarily in a quiescent state.
For example, histologic and ex vivo cell culture studies
of mouse tissues suggest that neural stem cells lie within
a vascular niche in which endothelial cells regulate stem
cell self-renewal (Louissaint et al., 2002; Palmer et al.,
2000; Ramirez-Castillejo et al., 2006; Shen et al., 2004).
Thus, CSCs might arise from normal stem cells that
have acquired mutations that enable them to escapeSIGNIFICANCE
Wepresent evidence that brain tumors orchestrate vascular niches thatmaintain the CSCpool. Disruption of these
niche microenvironments ablates the fraction of self-renewing cells in brain tumors and arrests tumor growth. Our
data identify a potential role for niche microenvironments in the maintenance of brain CSCs and identify a mech-
anism by which antiangiogenic drugs inhibit brain tumor growth.Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc. 69
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tively, deregulation of extrinsic factors within the niche
might lead to uncontrolled proliferation of stem cells and
tumorigenesis (Clarke and Fuller, 2006). If CSCs depend
upon aberrant niche microenvironments, then these
niches might represent targets for treatments of cancer.
Here, we demonstrate that Nestin+/CD133+ cancer
cells that include the CSC fraction are located next to
capillaries in brain tumors. We show further that endothe-
lial cells interact selectively with Nestin+/CD133+ brain
cancer cells in culture and supply secreted factors that
maintain these cells in a self-renewing and undifferenti-
ated state. Increasing the number of endothelial cells or
blood vessels in orthotopic brain tumor xenografts ex-
panded the numbers of self-renewing Nestin+/CD133+
cancer cells and accelerated the initiation and growth of
tumors. Conversely, antiangiogenic therapies depleted
tumor blood vessels and associated self-renewing
Nestin+/CD133+ cancer cells from xenografts and ar-
rested tumor growth. Thus, we propose that the brain
tumor microvasculature forms niche microenvironments
that maintain CSCs and that represent therapeutic targets
in brain tumors.
RESULTS
Nestin+ Brain Tumor Cells Associate
with the Tumor Vasculature
Normal neural stem and precursor cells and brain CSCs
express the major intermediate filament protein Nestin
(Galli et al., 2004; Hemmati et al., 2003; Palmer et al.,
2000; Singh et al., 2004; Taylor et al., 2005). In the hippo-
campus, Nestin+ cells are located close to capillaries
where endothelial cells are believed to regulate the self-
renewal and differentiation of stem cell daughters (Palmer
et al., 2000; Wurmser et al., 2004). As a first step to estab-
lish if brain CSCs are located within a vascular niche, we
determined the incidence of Nestin+ cells, and the proxim-
ity of these cells to tumor capillaries in sections of medul-
loblastoma (n = 20), ependymoma (n = 23), oligodendro-
glioma (n = 20), and glioblastoma (n = 10).
In keeping with the low incidence of CSCs within brain
tumors (Galli et al., 2004; Singh et al., 2004; Taylor et al.,
2005), between 0.15% and 0.22% of cells within tumors
were Nestin+ (>500 cells counted per tumor section;
Figure 1A). The number of Nestin+ cells in brain tumors ap-
peared to correlate with microvessel density (MVD): oligo-
dendrogliomas and glioblastomas that had the highest
MVD also contained the greatest numbers of Nestin+ cells
(Figure 1A). Further, Nestin+ cells were located signifi-
cantly closer to tumor capillaries than Nestin cells, inde-
pendent of histologic diagnosis (Figures 1A and 1B).
Since individual tumor sections represent three dimen-
sional tissues in only two dimensions, it is difficult using
standard histology to determine the precise relationship
between individual cells and the vasculature (Palmer
et al., 2000). Therefore, we used multiphoton laser-
scanning microscopy to reconstruct, in three dimensions,
serial images taken through 50 mm sections of four70 Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc.gliomas that were coimmunostained for CD34 and Nestin
(70 images per section). This analysis showed clearly
that Nestin+ tumor cells directly contact tumor capillaries
(Figure 1C).
Endothelial cells have been reported to express Nestin
(Aihara et al., 2004). However, the morphology of Nestin+
cells in brain tumors was more typical of neural stem cells,
and less than 0.1% of these cells coexpressed the endo-
thelial marker CD34. Furthermore, 73.4% ± 20% of Nes-
tin+ cells in tumor sections coexpressed the cell surface
protein CD133, which marks quite specifically normal
neural stem and precursor cells and brain CSCs (>800
cells counted per tumor; Figure 1D) (Singh et al., 2004;
Taylor et al., 2005; Uchida et al., 2000).
Focusing on medulloblastoma, we next sought to deter-
mine if Nestin+ cells in brain tumors are cancer cells or
entrapped normal neural stem and precursor cells. First,
we performed consecutive coimmunofluorescence (Nes-
tin and CD34) and fluorescence in situ hybridization
(FISH) analysis of sections of medulloblastomas that
we had shown previously to contain an isochromosome
of 17q (Thompson et al., 2006). Over one-third of the
Nestin+-vessel-associated cells in these tumors con-
tained an isochromosome 17q, confirming that they are
cancer cells (Figure 1D). It is likely that a greater proportion
of Nestin+ cells in these tumors are cancer cells, since
FISH underestimates the frequency of low-copy-number
cytogenetic alterations because portions of cell nuclei
are lost during tissue sectioning. Indeed, Ki-67/Nestin
coimmunofluorescence demonstrated that 29.1% ±
11.6% of Nestin+ cells in these tumors are proliferating
(>500 cells counted per section; Figure 1D). Less than
1% of cells in the normal human subventricular zone
express Ki-67 (Quinones-Hinojosa et al., 2006; Sanai
et al., 2004). Therefore, Nestin+ cells in medulloblastoma
appear to possess aberrant proliferative capacity, sug-
gesting further that they are cancer cells.
Finally, we prelabeled Daoy (Jacobsen et al., 1985) and
MEB-MED-8A (Pietsch et al., 1994) medulloblastoma cells
with green fluorescence protein (GFP) by retroviral trans-
duction and transplanted 1 3 106 GFP+ cells orthotopi-
cally into the brains of immunocompromised mice (n = 3
mice per cell line). Engrafted Daoy and MEB-MED-8A cells
formed highly infiltrative primitive neuroectodermal tu-
mors (Figure 1E and data not shown). CSCs have been
identified in established brain tumor cell lines and are
responsible for the in vivo malignancy of these cells
(Kondo et al., 2004). In keeping with our analysis of
primary medulloblastomas, 0.83% and 1.3% of cells
in Daoy and MEB-MED-8A xenografts, respectively, ex-
pressed Nestin (>300 cells counted per tumor; Figure 1E),
and these cells were located significantly closer to capil-
laries (Daoy, 32 ± 3.3 mm; MEB-MED-8A, 44 ± 5.6 mm)
than were Nestin cells (Daoy, 74 ± 2.5 mm; MEB-MED-
8A, 80 ± 3.6 mm; p < 0.0001 for both cell lines). Nestin+
cells in these xenografts coexpressed GFP, confirming
that they are cancer cells (Figure 1E). Together, these
data indicate that the great majority of Nestin+ cells in
brain tumors are vessel-associated cancer cells.
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A Brain Tumor Stem Cell NicheFigure 1. Nestin+ Cells in Brain Tumors Are Located Next to Capillaries
(A) Coimmunofluorescence analysis of Nestin and CD34 expression in sections of a primary medulloblastoma (MB), ependymoma (EP), oligodendro-
glioma (OLIG), and glioblastoma (GBM). Arrows indicate Nestin+ cells. The microvessel density (MVD) and percentage Nestin+ tumor cells are shown
for each tumor type.
(B) Graph reports the percentage of Nestin+ and Nestin cells that were located in incremental distances of 5 mm from the nearest CD34+ endothelial
cell in each tumor type (**p < 0.005, ***p < 0.0005 for the average distance of Nestin+ versus Nestin cells from CD34+ cells).
(C) Reconstruction in three dimensions of capillaries (CD34, red) and Nestin+ tumor cells (green) in 50 mm sections of two gliomas.
(D) Nestin and CD133 coimmunofluorescence (left), concurrent coimmunofluorescence (Nestin/CD34) and FISH (17p/17q) (middle), and coimmuno-
fluorescence (Nestin/Ki-67) staining (right) of primary medulloblastoma. Asterisks marks a capillary lumen.
(E) Hematoxylin and eosin staining (left), Nestin and GFP coimmunofluorescence (middle), and Nestin and CD34 coimmunofluorescence (right)
of orthotopic xenografts of GFP+ Daoy medulloblastoma cells. Arrows indicate Nestin+ cancer cells. All nuclei are stained with DAPI.CD133+ Brain Tumor Cells Interact Physically
with Endothelial Cells in Culture
To investigate further if brain CSCs interact directly with
endothelial cells, we prepared single-cell suspensionsfrom a freshly resected primary medulloblastoma (MB5)
and ependymoma (EP1) that we obtained direct from the
operating room and labeled these with a green fluorescent
dye (PKH67). We then used antibody-based cell sorting toCancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc. 71
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A Brain Tumor Stem Cell NicheFigure 2. CD133+ Brain Tumor Cells
Associate with Endothelial Cells in 3D
Matrigel Cultures
(A) Overlay of phase-contrast and autofluores-
cence photomicrographs of unlabeled endo-
thelial cells or astrocytes that were cocultured
with CD133+ or CD133 green fluorescence-
labeled primary medulloblastoma (MB5) or
ependymoma (EP1) cells.
(B) The number of green fluorescent (tumor
cells) that contacted directly an unlabeled cell
(endothelial or astrocyte) was determined by
high-power microscopic review of cocultures.
The reviewer was blinded to CD133 tumor
cell status. Graph reports the percentage of
CD133+ and CD133 tumor cells in each co-
culture that formed a direct contact with cocul-
tured cells. Each bar is marked with the total
number of tumor cells in each culture (*p <
0.05, **p < 0.005, ***p < 0.0005 reports the
difference between CD133+ and CD133
tumor cell contacts with cocultured cells).isolate CD133+ cells from these brain tumors since this
fraction is enriched for CSCs (Singh et al., 2004; Taylor
et al., 2005). Subsequent karyotype analysis of these
tumor cells that we have reported elsewhere confirmed
that they are cancer cells (Taylor et al., 2005). We similarly
fractionated populations of Daoy medulloblastoma cells.
We then mixed CD133+ or CD133 tumor cells with pri-
mary human endothelial cells (PHECs) in a 3D matrigel
assay in which the endothelial cells form vascular tubes
(n = 8 separate cultures per cell population).
PHECs formed vascular tubes within 5–7 hr indepen-
dent of the CD133 status of the cocultured tumor cells
(Figure 2A). CD133+ tumor cells, independent of origin, as-
sociated rapidly with endothelial vascular tubes, forming
intimate contacts often along the entire length of an endo-
thelial tube (Figures 2A and 2B). In contrast, significantly
fewer CD133 tumor cells made contacts with endothelial
cells and generally remained rounded and separate from
the vascular-like structures. To control for the possibility
that CD133 tumor cells are unable to form cell-cell con-
tacts in 3D matrigel cultures, we repeated these ex-
periments using primary human astrocytes (PHAs) instead
of PHECs. Both CD133+ and CD133 tumor cells inter-
acted readily, but not differently, with PHAs in these cocul-
tures (Figures 2A and 2B). Thus, CD133+ brain tumor cells
that contain the CSC fraction, but not CD133 cells,
interact closely with vascular endothelial cells in culture.72 Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc.Endothelial Cells Maintain Self-Renewing
and Undifferentiated Brain Tumor Cells
Endothelial cells secrete soluble factors that maintain the
self-renewal and undifferentiated phenotype of normal
neural stem cells (Ramirez-Castillejo et al., 2006; Shen
et al., 2004). To test if endothelial-derived factors similarly
maintain self-renewing brain tumor cells, we first pas-
saged tumor spheres of CD133+ cells that we isolated
from a primary medulloblastoma (MB1), a primary epen-
dymoma (EP1), and the Daoy medulloblastoma cell line,
under conditions that promote stem cell growth (Taylor
et al., 2005). Tumor spheres derived from each of these
cell populations could be passaged serially and ex-
pressed CD133 and Nestin, confirming that these are clo-
nogenic, self-renewing stem-like cells (Figures 3A–3C). We
then transferred tertiary tumor spheres of these cells to the
base of culture wells while the upper transwell compart-
ment was seeded with PHECs or control cells (CD133 tu-
mor cells, fibroblasts, or PHAs) (Figure 3D). This transwell
system allows the exchange of diffusible factors, but not
cells, between chambers. Cocultures were maintained
for 2 weeks in reduced-serum-containing medium.
Tumor spheres that were cocultured with PHECs in-
creased in size and after 2 weeks were up to five times
larger than those grown in the presence of control cells
(Figure 3E). Further, significantly more PHEC-cocultured
tumor spheres remained as intact CD133+/Nestin+ tumor
Cancer Cell
A Brain Tumor Stem Cell NicheFigure 3. Endothelial Cells Maintain Self-Renewing and Undifferentiated Brain Tumor Cells in Culture
(A–C) CD133 and Nestin immunofluorescence analysis of Daoy (A)-, primary medulloblastoma (MB1) (B)-, and primary ependymoma (EP1)
(C)-derived tertiary tumor spheres.
(D) Cartoon depicting the experimental approach adopted to determine the ability of PHECs to maintain the self-renewal and undifferentiated
phenotype of brain tumor cells.
(E) Comparison of the size (top images: DAPI staining of four representative tumor spheres; top graph: average total sphere area of tumor spheres in
the appropriate cultures), maintenance (bottom graph: percentage of tertiary tumor spheres remaining after 120 hr of coculture), and self-renewal
(bottom figures report the percentage of quaternary-forming tumor spheres derived from cocultured tertiary spheres) of Daoy medulloblastoma cells
and primary medulloblastoma (MB1) and primary ependymoma (EP1) cells cocultured with PHECs (+) or control cells (). Results are shown for
differentiated tumor cells as controls. Similar results were obtained when PHAs or fibroblasts were used as controls (*p < 0.05, **p < 0.005, exact
Wilcoxon test).spheres compared to those cultured with control cells.
Thus, PHECs maintained the proliferation of tumor sphere
cells even under reduced-serum conditions that caused
control cultured spheres to disaggregate, spread outover the culture surface, and lose expression of CD133
and Nestin (Figure 3E and data not shown).
To test if PHECs maintained also the self-renewal
capacity of brain tumor cells, we disaggregated tertiaryCancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc. 73
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either PHECs or control cells and reseeded suspensions
of these cells in stem cell culture medium that was serum
free (Figure 3D). Although we were unable to recover any
quaternary tumor spheres from cultures of MB1 cells,
both Daoy- and EP1-derived sphere cells that had been
cocultured with PHECs were significantly more likely to
generate quaternary tumor spheres than cells isolated
from control cocultures (Figure 3E). These data identify
striking similarities between normal neural stem cells
and self-renewing brain tumor cells and suggest that
stem-like properties of brain CSCs are enhanced by
endothelial-cell-secreted factors.
Endothelial Cells Promote the Propagation of Brain
Tumors In Vivo
If endothelial-derived factors support the self-renewal of
brain CSCs, then we reasoned that endothelial cells
should promote the propagation of brain tumors in vivo.
To test this, we injected 1 3 106 unsorted GFP+ Daoy
medulloblastoma cells either alone or in combination
with red fluorescence dye (PKH26)-labeled PHECs, under
cranial windows in the cerebral cortex of immunocompro-
mised mice (nR 3 mice per cell mix). Tumor cells (green)
were readily distinguished from endothelial cells (red)
using dual-color fluorescence microscopy (Figure 4A).
Injections of GFP+ Daoy cells alone resulted in a steady
increase in tumor fluorescence (green) that could be
detected using intravital fluorescence microscopy via
the cranial window, and that correlated closely with
increasing tumor burden (Figure 4A and Figure S1 in the
Supplemental Data available with this article online).
Tumor fluorescence reached a peak in these mice at
around 7 weeks postinjection, at which point the animals
succumbed to their disease (mean peak fluorescence at
7 weeks; 526 ± 176 SD; n = 6 independent animals; see
Figure S1). Remarkably, 13 106 GFP+ Daoy medulloblas-
toma cells that were coinjected with 100,000 PHECs
formed tumors much more rapidly, reaching peak tumor
burden after only 4 weeks (Figure 4A). This acceleration
of xenograft growth occurred in a cell-dose- and cell-
specific manner: increasing numbers of coinjected PHECs
produced a stepwise increase in tumor growth rate, but
coinjection of PHAs did not affect xenograft growth
(Figure 4A). Red fluorescence declined steadily in PHEC/
tumor cell xenografts, since the half-life of PKH26 dye
in vivo is 2 weeks. Thus, the increasing tumor fluores-
cence in these xenografts resulted entirely from the ex-
pansion of the tumor cell population.
Xenografts that were established in the presence of
PHECs contained up to 25 times more Nestin+/GFP+
tumor cells than did xenografts of Daoy cells alone (cells
detected by Nestin/GFP coimmunofluorescence; Fig-
ure 4B). PHECs (differentiated from endogenous mouse
endothelial cells using a human CD34-specific antibody;
Figure S2) coclustered with Nestin+/GFP+ tumor cells
in xenografts (Figure 4C). Importantly, PHECs remained
separate from tumor capillaries and did not increase the
MVD of xenografts relative to that observed in tumors74 Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc.formed by GFP+ Daoy cells alone (data not shown).
Together, these data suggest the hypothesis that endo-
thelial cells contribute specific factors to the tumor micro-
environment that expand the CSC pool and accelerate the
initiation and/or growth of brain tumor xenografts.
To test more directly if endothelial cells promote tumor
growth by supporting CSCs, and if freshly resected pri-
mary tumor cells are responsive to these signals, we
repeated our cranial window transplant experiments using
50,000 CD133+ or CD133 cells that we isolated from
two primary medulloblastomas (MB4 and MB5). Primary
tumor cells were obtained direct from the operating room,
GFP-labeled by lentiviral transduction, and then trans-
planted as described below after less than four passages
in culture. Two out of every three primary medulloblasto-
mas can be expected to generate tumors following ortho-
topic transplant of 50,000 CD133+ tumor cells, but no
significant tumor growth has been reported from injec-
tions of CD133 tumor cells (Singh et al., 2004). As ex-
pected, CD133 primary tumor cells grew only transiently
(MB4) or not at all (MB5) as transplants, even in the pres-
ence of coinjected PHECs (Figure 5). In contrast, CD133+
tumor cells formed fluorescent masses within 7 days
of injection. The growth of CD133+ cell masses was
enhanced dramatically by the presence of PHECs and
resulted in the formation of a rapidly growing tumor in
mice that were injected with CD133+ MB5 cells. While
coinjection of PHECs also enhanced initially the growth
of transplanted CD133+ MB4 cells, the growth of these
tumor cells was not sustained. Together, these data
support the hypothesis that endothelial cells contribute
to a niche microenvironment that promotes the initiation
of brain tumors by CSCs.
Depletion of Brain Tumor Blood Vessels Eradicates
Self-Renewing Tumor Cells
Our finding that endothelial-derived factors enhance the
initiation of brain tumors by CD133+ tumor cells suggests
that antiangiogenic drugs could inhibit brain tumor
growth, at least in part, by disrupting a CSC vascular
niche. To test this, we investigated the impact of antian-
giogenic therapies on the numbers of self-renewing tumor
cells in, and growth of, medulloblastoma and glioma
orthotopic xenografts.
Angiogenic signaling in tumors is often initiated by
oncogenic cell signal pathways (Jain et al., 2006). There-
fore, we first upregulated angiogenic signaling in GFP+
Daoy cells by transfection with the ERBB2 oncogene
(DaoyERBB2). ERBB2 is overexpressed in aggressive forms
of medulloblastoma (Gajjar et al., 2004) and elicits a cell
signal that upregulates vascular endothelial growth factor
(VEGF) (Saucier et al., 2004). DaoyERBB2 cells secreted
60-fold more VEGF than did vector control (DaoyV) cells,
and treatment of these cells with Erlotinib—a selective in-
hibitor of the EGFR and ERBB2 tyrosine kinases (Akita and
Sliwkowski, 2003)—or an anti-ERBB2 siRNA downregu-
lated VEGF expression (see Figures S3A and S3B). We
then established orthotopic xenografts of 1 3 106 GFP+
DaoyERBB2 or DaoyV cells under cranial windows in the
Cancer Cell
A Brain Tumor Stem Cell NicheFigure 4. Endothelial Cells Promote the Growth of Orthotopic Brain Tumor Xenografts
(A) The first column shows autofluorescence micrographs of mixed suspensions of GFP+ Daoy cells (green) and PHECs or PHAs (red) just prior to
orthotopic injection. Numbers of PHECs and PHAs are in thousands. Subsequent columns show overlaid intravital red and green fluorescence pho-
tomicrographs of xenografts that were captured via the cranial window at the indicated time intervals following transplantation. Numbers report the
level of green and red fluorescence in each xenograft at each time point (percentage of day 0 value).
(B) Coimmunofluorescence (Nestin and human-specific CD34) analysis of the orthotopic xenografts in (A) that were established by transplantation of
Daoy cells alone (left) or Daoy cells plus 500 3 103 PHECs (right). Numbers at the bottom of each photomicrograph report the percentage of Nestin
(green) and human CD34 (red)-expressing cells in each tumor (**p < 0.005, exact Wilcoxon test).
(C) Map of the distribution of Nestin and human CD34-expressing cells across an entire section of a Daoy orthotopic xenograft that included 5003 103
PHECs. The map was generated from a composite review of high-power coimmunofluorescence photomicrographs.Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc. 75
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A Brain Tumor Stem Cell NicheFigure 5. Endothelial Cells Promote the Initiation of Orthotopic Brain Tumor Xenografts by CD133+, but Not CD133 Primary
Medulloblastoma Cells
Autofluorescence photomicrographs of the growth of orthotopic xenografts of 50,000 GFP-labeled CD133+ or CD133 cells that we isolated from two
primary medulloblastomas (MB4 and MB5) and transplanted orthotopically under cranial windows into the cerebral cortex of nude mice. Tumor cells
were transplanted alone or with 50,000 red fluorescence-labeled PHECs. The first column shows autofluorescence micrographs of cells immediately
prior to transplantation. Subsequent columns show overlaid intravital red and green fluorescence microscopy images of tumors captured via the cra-
nial window at the indicated time intervals following implantation. Numbers report the level of green and red fluorescence in each xenograft at each
time point (percentage of day 0 value).cerebral cortex of nude mice. To target both the ‘‘up-
stream’’ and ‘‘downstream’’ components of angiogenic
signaling in this model, we treated tumor-bearing mice
with either Erlotinib (50 mg/kg/23 day for 5 days), which
abolishes ERBB2 signaling in vivo (Hernan et al., 2003);
a single dose of 10 mg/kg of the anti-VEGF monoclonal
antibody Bevacizumab; or vehicle-only control (n = 10
mice bearing each xenograft for each treatment). Tumors
were then excised and analyzed as outlined in Figure 6A.76 Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc.As expected, DaoyERBB2 xenografts expressed much
higher levels of VEGF, contained a significantly higher
MVD (compare vehicle-only treated tumors in Figures 6B
and 6C), and grew more rapidly following transplantation
(Figure S4) than did DaoyV tumors. Also, single-cell
suspensions of excised DaoyERBB2 tumors generated
five times more self-renewing CD133+/Nestin+ tumor
spheres than cells from DaoyV tumors (compare vehicle-
only treated tumors in Figure 6D). All tumor sphere cells
Cancer Cell
A Brain Tumor Stem Cell NicheFigure 6. Antiangiogenic Therapy De-
pletes the Tumor Vasculature, Ablates
Self-Renewing Tumor Cells, and Inhibits
the Growth of DaoyERBB2 Orthotopic
Xenografts
(A) Cartoon depicting the experimental
approach adopted to determine whether
depletion of blood vessels from brain tumors
ablates the CSC fraction.
(B–G) Graphs (all error bars = mean ± SE)
report VEGF expression levels (B), microvessel
density (C), self-renewal capacity (serial tumor
sphere-forming assay) (D), growth (tumor
fluorescence) (E), apoptosis (TUNEL) (F), and
proliferation (Ki67 labeling) (G) of vehicle
(‘‘V’’)-, Erlotinib (‘‘E’’)-, or Bevacizumab (‘‘B’’)-
treated DaoyERBB2 and DaoyV orthotopic xeno-
grafts (*p < 0.05, **p < 0.005, ***p < 0.0005,
exact Wilcoxon test).
(H) Coimmunofluorescence analysis of tumor
spheres formed ex vivo by cells that were
derived from vehicle-treated DaoyERBB2 and
DaoyV xenografts.coexpressed GFP, confirming that they were derived from
transplanted tumor cells and not normal mouse cells
(Figure 6H), and displayed evidence of multipotencywhen cultured under conditions that promote differentia-
tion (Figure S5). Importantly, ERBB2 signaling in Daoy
cells does not impact directly cell proliferation, apoptosis,Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc. 77
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A Brain Tumor Stem Cell Nicheor self-renewal (see Figures S6A to S6D). Thus, expansion
of the tumor vasculature in DaoyERBB2 relative to DaoyV
tumors was associated with an increased number of self-
renewing, multipotent cancer cells.
Both Erlotinib and Bevacizumab treatments induced
a profound antiangiogenic response in DaoyERBB2 xeno-
grafts that was associated with significant tumor growth
arrest (Figures 6B, 6C, and 6E). Interestingly, despite
these marked antiangiogenic and growth inhibitory
effects, neither drug altered the level of apoptosis or
necrosis in DaoyERBB2 xenografts, and only Erlotinib
decreased slightly cell proliferation in these tumors rela-
tive to vehicle treatment (Figures 6F and 6G and data
not shown). However, both drugs resulted in a complete
loss of self-renewing GFP+/Nestin+/CD133+ tumor cells
from single-cell suspensions of treated DaoyERBB2 xeno-
grafts (Figure 6D). In stark contrast, since the ERBB2-
VEGF axis in DaoyV tumors is much less active than in
DaoyERBB2 xenografts, neither Erlotinib nor Bevacizumab
affected the MVD in DaoyV tumors (Figure 6C). In agree-
ment with our hypothesis, these treatments also failed to
alter the number of self-renewing GFP+/Nestin+/CD133+
cells in DaoyV tumors (Figure 6D). Although both Erlotinib
and Bevacizumab therapy produced a moderate increase
in DaoyV tumor cell apoptosis that presumably resulted
from blockade of endogenous EGFR/ERBB2 and VEGF
signaling, this did not impact tumor growth (Figures 6E
and 6F). Importantly, neither Erlotinib nor Bevacizumab
affect directly the self-renewal, proliferation, or apoptosis
of Daoy cells in culture (see Figure S6E and data not
shown). Together, these data provide strong support for
the hypothesis that brain tumor growth depends critically
upon the presence of an intact CSC vascular niche and
identifies this niche as a potential target for treatments
of brain tumors. As a first step to determine if this thera-
peutic approach might have clinical benefit, we treated
DaoyERBB2 and DaoyV tumor-bearing mice for 2 weeks
with 50 mg/kg/23 day of Erlotinib (n = 8 mice with each
tumor per treatment). Erlotinib prolonged significantly
the survival of mice bearing DaoyERBB2 tumors (median
survival of Erlotinib-treated mice = 66 ± 3.4 days versus
45 ± 2.9 days in vehicle-treated mice; exact log rank p <
0.05), but not those harboring DaoyV xenografts (median
survival of Erlotinib-treated mice = 53 ± 2.8 days versus
54 ± 3.1 days in vehicle-treated mice; log rank p = 0.73).
Finally, since ongoing clinical trials of Bevacizumab
suggest that this drug has promising therapeutic activity
against glioblastoma (Reardon and Wen, 2006), we inves-
tigated if Bevacizumab might deplete self-renewing can-
cer cells from this brain tumor. To do this, we treated
with Bevacizumab or vehicle mice bearing orthotopic xe-
nografts of U87 glioma cells that express the Luciferase
reporter gene (U87GLuc). Transplantation of 1 3 106
U87Luc cells into the brains of immunocompromised
mice resulted in the formation of brain tumors that could
be detected readily using bioluminescence (Figure 7A).
As we observed in DaoyERBB2 medulloblastoma xeno-
grafts, a single dose of 10 mg/kg Bevacizumab, but
not vehicle, reduced markedly the MVD and growth of78 Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc.U87Luc tumors (n = 5 mice per treatment group; Figures
7A–7C). Furthermore, Bevacizumab decreased pro-
foundly the numbers of vessel-associated Nestin+ tumor
cells in U87Luc xenografts and the number of self-renew-
ing GFP+/Nestin+/CD133+ tumor cells that could be recov-
ered from these tumors, without impacting tumor cell pro-
liferation, apoptosis, or necrosis (Figures 7A and 7D–7G
and data not shown). Interestingly, residual Nestin+ cells
in Bevacizumab-treated glioma xenografts were not dis-
tributed randomly through tumors but were associated
with persisting tumor vessels (Figure 7A). Thus, we pro-
pose that antiangiogenic drugs arrest brain tumor growth,
at least in part, by disrupting a vascular niche microenvi-
ronment that is critical for the maintenance of CSCs.
DISCUSSION
Evidence suggests that normal neural stem cells exist in
vascular niches, into which endothelial cells secrete fac-
tors that regulate neural stem cell function (Palmer et al.,
2000; Ramirez-Castillejo et al., 2006; Shen et al., 2004).
Here, we provide several lines of evidence that the brain
tumor microvasculature forms a niche that is critical for
the maintenance of CSCs.
Since niches control stem cell function, it may seem
counterintuitive that CSCs would be located within these
regulatory microenvironments. However, our data support
the hypothesis that vascular niches in brain tumors are
abnormal and contribute directly to the generation of
CSCs and tumor growth. In the normal brain, neural
stem cell niches are restricted to the hippocampus and
subventricular zones where rates of cell proliferation are
quite low (Sanai et al., 2005). In contrast, we found that
a significant proportion of vessel-associated Nestin+
tumor cells are proliferating, and that these cells are dis-
tributed throughout tumors, from all regions of the cere-
brum and cerebellum. We show further that PHECs main-
tain self-renewing brain tumor cells in culture and promote
the initiation and growth of orthotopic brain tumor xeno-
grafts. Increasing the number of capillaries in orthotopic
brain tumors also expanded dramatically the number of
self-renewing and multipotent cells contained in these
tumors. Therefore, we propose that the tumor microvas-
culature generates specific niche microenvironments
that promote the formation and/or maintenance of brain
CSCs. Interestingly, atypical ectopic perivascular niches
were recently described around perivascular areas of
the inflamed CNS (Martino and Pluchino, 2006). These
entities behave as anatomically atypical, although highly
specialized, ectopic niches that regulate long-term sur-
vival and behavior of transplanted neural stem cells.
Thus, atypical and ectopic stem cell niches might play
central roles in a number of nervous system diseases,
including brain tumors.
If the recruitment of aberrant vascular niches is an
important component in the progression of brain tumors,
then this might explain why the most aggressive brain
tumors are highly angiogenic (Folkerth, 2004; Phillips
et al., 2006; Plate et al., 1992). Intriguingly, protein ligands
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A Brain Tumor Stem Cell NicheFigure 7. Bevacizumab Therapy De-
pletes the Tumor Vasculature, Ablates
Self-Renewing Tumor Cells, and Inhibits
the Growth of U87Luc Glioma Orthotopic
Xenografts
(A) Coimmunofluorescence analysis of Nestin
and CD34 expression in sections of glioma
xenografts 1 week following treatment with
Bevacizumab or vehicle. Arrows point to
Nestin+ cells. Bioluminescence images of
these tumors generated prior to excision are
shown above.
(B–G) Graphs (all error bars = mean ± SE)
report tumor growth (bioluminescence) (B),
microvessel density (C), percentage Nestin+
cells (D), self-renewal capacity (serial tumor
sphere-forming assay) (E), apoptosis (TUNEL)
(F), and proliferation (Ki67 labeling) (G) of vehi-
cle (‘‘V’’)- and Bevacizumab (‘‘B’’)-treated
xenografts (*p < 0.05, **p < 0.005, exact
Wilcoxon test).that are found within the neural stem cell niche have been
shown to regulate both stem cell self-renewal and angio-
genesis, suggesting further that these two processes are
linked. For example, KIT ligand (also known as stem cell
factor), which is a potent glioma-derived proangiogenic
factor (Sun et al., 2006), also promotes the migration, sur-
vival, and proliferation of neural progenitor cells (Erlands-
son et al., 2004; Jin et al., 2002), and PEDF, which main-
tains neural stem cell self-renewal, is a potent regulator
of angiogenesis (Pumiglia and Temple, 2006; Ramirez-
Castillejo et al., 2006). Furthermore, very recent studies
of orthotopic glioblastoma xenografts suggest that
CSCs of this brain tumor secrete angiogenic factors that
promote the recruitment and formation of tumor blood
vessels (Bao et al., 2006). It is noteworthy that VEGFR-
1+ bone marrow progenitor cells were shown recently to
form niches at the sites of lung and melanoma tumor
metastasis (Kaplan et al., 2005), and that bone marrow
endothelial niches are required for the homing and reten-
tion of normal hematopoietic and leukemic stem cells (Kiel
et al., 2005; Sipkins et al., 2005). In the brain, the formationof multiple vascular CSC niches, each with the capacity to
generate numerous tumor cells, might facilitate signifi-
cantly brain tumor growth and invasion.
As well as regulating stem cell proliferation and cell-fate
decisions, niches also play a protective role, shielding
stem cells from environmental insults. Thus, vascular
niches might protect brain CSCs from chemo- and radio-
therapies, enabling these cells to reform a tumor mass
following an initial clinical response. Evidence indicates
that endothelial cells can protect stem cells and tumor
cells from radiation damage (Garcia-Barros et al., 2003;
Paris et al., 2001). For example, solid tumor xenografts
grown in mice with radiation-resistant endothelial cells
are much less sensitive to radiation damage than tumors
grown in wild-type mice (Garcia-Barros et al., 2003). Our
data suggest a mechanism, at least in brain tumors, by
which endothelial cells might promote tumor radioresist-
ance. Further, studies of the hematopoietic stem cell niche
suggest that niche microenvironments can promote cell
survival signals in CSCs, enabling them to resist chemo-
therapies (De Toni et al., 2006; Dick and Lapidot, 2005).Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc. 79
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A Brain Tumor Stem Cell NicheIf the notion that niches protect CSCs proves correct,
then targeting these microenvironments could prove
a highly effective treatment of cancer. We found that anti-
angiogenic therapies including Bevacizumab deplete
tumor blood vessels and self-renewing cancer cells from
orthotopic models of medulloblastoma and glioma, result-
ing in tumor growth arrest. Notably, VEGF has been shown
to enhance the survival of neural stem cells (Wada et al.,
2006). Thus VEGF-specific inhibitors like Bevacizumab
might impact brain tumor growth by targeting both a vas-
cular niche and the associated CSCs. Exciting early data
from clinical trials of Bevacizumab combined with the che-
motherapeutic drug CPT-11 suggest that this combina-
tion is one the most effective treatments of glioblastoma
identified to date (Reardon and Wen, 2006). In light of
our data, it is tempting to speculate that the activity of
this drug combination results from targeting CSCs, as
well as the disease bulk. This important mechanism of
drug action should be studied further in ongoing preclini-
cal and clinical trials of antiangiogenic drugs in brain
tumors.
EXPERIMENTAL PROCEDURES
Tumor Samples and Cell Lines
Tumor samples were obtained under protocol XPD01-092 (St. Jude
Children’s Research Hospital Institutional Review Board). Tumors
were immediately disaggregated into single-cell suspensions as
described in detail elsewhere (Taylor et al., 2005). Primary tumor cell
cultures were maintained in Neurobasal medium (Invitrogen) contain-
ing 2 mM L-glutamine, N2 supplement (Invitrogen), B27 supplement
(Invitrogen), 20 ng/ml hrEGF (Invitrogen), 20 ng/ml hrbFGF (Invitrogen),
and 50 mg/ml BSA. All experiments were conducted at cell passage <4.
Previous cytogenetic studies showed that all cultured primary tumor
cells were cancer cells (Taylor et al., 2005). PHECs, U87, and Daoy
cells were obtained from the ATCC (Manassas, VA). PHAs were from
Cambrex, MD. PHECs were cultured in endothelial cell growth medium
(EGM) containing 2% fetal bovine serum (GIBCO, USA). PHAs were
cultured in astrocyte growth medium that contains 2% serum (AGM,
Cambrex). Daoy cells were transfected with the complete coding re-
gion of ERBB2 (DaoyERBB2) or vector control (DaoyV), and U87 glioma
cells with the luciferase reporter, as described (Hernan et al., 2003).
GFP was expressed in DaoyV and DaoyERBB2 by transduction with
MSCV-IRES-GFP retrovirus. Primary tumor cells were labeled green
by GFP-lentiviral transduction. GFP+ tumor cells were isolated by
fluorescence-activated cell sorting (FACS). Daoy and U87 cells were
maintained under standard culture conditions in DMEM containing
10% FCS unless otherwise specified.
Tumor Sphere Initiation Assays
Single-cell suspensions were made in Neurobasal medium in 96-well
plates (diluted as 10,000 to 1 cells/well). The number of tumor spheres
that formed subsequently per well was quantified after 14 days. Tumor
spheres were then disaggregated and reseeded to evaluate self-
renewal by formation of secondary tumor spheres. Where indicated,
this process was repeated to form tertiary and quaternary tumor
spheres.
Coculture Studies
For transwell coculture studies, tumor spheres were added in 500 ml
of culture medium to each well of a 24-well coculture plate (BD Biosci-
ences). Transwell inserts containing 0.4 mm diameter membrane pores
that allow the passage of diffusible molecules, but not cells, were then
placed into each well and seeded with 13 104 PHECs or control cells80 Cancer Cell 11, 69–82, January 2007 ª2007 Elsevier Inc.(see text). Plates were then incubated under standard culture condi-
tions in medium containing 2% fetal calf serum for 120 hr, and the num-
ber of remaining tumor spheres was counted using phase-contrast
microscopy. The self-renewal of tumor sphere cells cocultured with
PHECs or control cells was determined using the tumor sphere initia-
tion assay described above. The differentiation of tumor sphere cells in
cocultures was determined by seeding tumor spheres in culture wells
on coated coverslips (poly-D-lysine/laminin) (BD Biosciences); tumor
cells were then fixed with 4% paraformaldehyde and analyzed by
immunofluorescence using previously published antibodies and tech-
niques (Taylor et al., 2005). Neurosphere size was measured by analyz-
ing3200 magnification images of DAPI-stained tumor spheres and the
ImageJ analysis tool (http://rsb.info.nih.gov/ij/).
For Matrigel coculture studies, GFP+ DaoyV or DaoyERBB2 cells or
primary tumor cells prelabeled with PKH67 (Sigma) were sorted using
CD133-antibody-coated magnetic beads (100 ml/108 cells; Miltenyi
Biotec) as described (Taylor et al., 2005). Purity of CD133 populations
was confirmed by CD133 immunofluorescence. Sorted tumor cells
(6000 cells/ml) were cultured ± PHECs or PHAs (10,000 cells/ml) in
Matrigel-coated (35 ml; BD BioScience) 8-well culture slides (BD Bio-
Science) overnight at 37C. PHECs or PHAs were imaged by phase-
contrast microscopy, and sorted cells expressing GFP or stained
with PKH67 were imaged using fluorescence microscopy.
Generation and Treatment of Orthotopic Transplants
Female CD-1 nu/nu mice (Charles River) aged 6–8 weeks were anes-
thetized and placed into stereotactic apparatus equipped with a Z
axis (Kopf instruments). A small portion of the scalp was removed,
a window (approximately 10 mm3 5 mm) was made in the skull using
a dental drill, and the pial layer was removed. Tumor cells (1 3 106 in
5 ml Matrigel) were implanted with or without PHAs or PHECs into
the cerebral surface at a depth of 0.5–2 mm using a 25 ml Hamilton
syringe with an unbeveled 30G needle. The wound was then covered
with a sterile glass window fixed in place using tissue adhesive. Imme-
diately following wound closure, implanted animals were transferred to
the intravital imaging system (Nikon, USA) and imaged to obtain
a baseline measurement, and animals were reanesthetized as required
for subsequent imaging. Data analysis was performed using Meta-
Morph Imaging software (Universal Imaging, Downington, PA). Mea-
surements were restricted to a fixed region within each image through-
out the course of the study and are presented as maximum
fluorescence (Fmax) normalized to minimum fluorescence (Fmin), which
compensated for potential interday variation in lamp intensity. U87Luc
xenografts were prepared in a similar manner through small cranial
burr holes without cranial windows. Tumor burden was measured in
U87Luc tumor-bearing mice by bioluminescence using a Series IVIS
Imaging System (Xenogen Corporation, Alameda, CA). Mice received
an intraperitoneal injection of 15 mg/ml D-luciferin (Xenogen) in sterile
PBS and were imaged 5 min later. All animals were imaged at a range
of 25 cm for 10 s. Acquired images were analyzed with the use of Living
Image Software version 2.50 (Xenogen). Bioluminescence measure-
ments were recorded as photons per second.
Erlotinib (OSI Pharmaceuticals) was administered to tumor-bearing
mice per os (p.o.) in a vehicle of 10% DMSO, 10% Cremephor in a
1% CMC solution. Animals were treated with Erlotinib (50 mg/kg/twice
daily) or vehicle for 5 days. Treatment was repeated where indicated
following a 2 day break. Bevacizumab (Genentech Inc.) was adminis-
tered by tail-vein injection at a dose of 10 mg/kg. All animal procedures
were conducted in accordance with all appropriate regulatory stan-
dards under protocol #356 (St. Jude Children’s Research Hospital
Animal Care and Use Committee).
Histologic, FISH, and Gene Expression Analysis
Dual-color FISH, immunofluorescence, immunohistochemical, and
TUNEL analyses of formalin-fixed, paraffin-embedded tumor samples,
xenografts, or cultured tumor cells were performed using immunore-
agents, FISH probes, and methods as described previously (Taylor
et al., 2005; Thompson et al., 2006). Nestin-specific antibodies
Cancer Cell
A Brain Tumor Stem Cell Nicheincluded a monoclonal antibody (Chemicon cat. no. MAB5326) that
recognizes the human but not the mouse protein and a polyclonal
antibody (Abcam) that recognizes human, mouse, and rat Nestin.
The distance between Nestin+ cells and CD34 endothelial cells was
measured in dual-immunofluorescence-stained images of brain tumor
sections using the line-measuring tool in ImageJ. In order to remove
observer bias and to allow analysis of large numbers of tumor sections,
immunohistochemical staining of xenografts, including assessment of
MVD (CD34 staining), was scored blind to the xenograft and treatment
using ImageJ software analysis. Briefly, images were processed at the
same magnification (3200) by removal of background hematoxylin
staining followed by monochromization. Monochrome images (giving
binary data: black areas of immunohistochemical stain and white non-
staining areas) were analyzed using ImageJ software, which calcu-
lated the absolute values for each channel, resulting in determination
of percentage of immunopositivity per unit area (constant 3200 field).
Two-photon microscopy was performed using an Ultima imaging
system (Prairie Technologies, Middletown WI), a Ti:sapphire Chame-
leon Ultra XR femtosecond-pulsed laser (920 nm) (Coherent, Santa
Clara, CA), and a 633 0.9 NA water-immersion IR objective (Olympus,
Center Valley, PA). Stacks of images were reconstructed in 3D using
Imaris software (Bitplane, Saint Paul, MN). VEGF mRNA expression
levels were determined in cultured cells and xenografts by reverse-
transcriptase real-time polymerase chain reaction analysis as
described previously (Thompson et al., 2006).
Supplemental Data
The Supplemental Data include six supplemental figures and can be
found with this article online at http://www.cancercell.org/cgi/
content/full/11/1/69/DC1/.
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